Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAL 2062

Next Previous
X
Search
Drug Profile

BAL 2062

Alternative Names: ASP-2397; GR-2397; VL-2397

Latest Information Update: 25 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Vical
  • Class Anti-infectives; Antifungals; Macrocyclic compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Invasive bronchopulmonary aspergillosis

Most Recent Events

  • 19 Sep 2024 Basilea enters into agreement with Biomedical Advanced Research and Development Authority (BARDA) to develop BAL 2062 for Fungal infections
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Invasive-bronchopulmonary-aspergillosis(In volunteers) in USA (SC, Injection)
  • 31 Oct 2023 Basilea Pharmaceutical announced the intention to initiate a phase II trial for Invasive bronchopulmonary aspergillosis in H1 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top